Ashira Blazer, MD;MS
University of Maryland Baltimore
Baltimore, Maryland, United States
Disclosure information not submitted.
Angela Crowley, MD
Staff Physician and Rheumatologist
Illinois Bone and Joint Institute, Hinsdale Orthopaedics
Hinsdale, IL, United States
Disclosure information not submitted.
Rajeev Raghavan, MD, FASN
Director
HCA Kingwood Internal Medicine Residency
Kingwood, TX, United States
Disclosure information not submitted.
Maria Dall'Era, MD
Director
UCSF
Corte Madera, CA, United States
Disclosure information not submitted.
This industry-sponsored symposium will discuss how the earlier use of biologics, supported by the 2023 EULAR recommendations, has the potential to change the systemic lupus erythematosus (SLE) disease course and improve patient outcomes. This interactive session will explore example patient cases where the early use of biologics should be considered and will discuss which factors clinicians find most important when considering biologic initiation. Example case studies for early biologic initiation include a patient with persistent disease activity unable to taper corticosteroids to 5 mg/day or less, a newly diagnosed patient with moderate disease activity despite antimalarial and corticosteroid use, and a patient with a flare after a gap in care. Attendees can expect to come away from the session with greater appreciation of the unmet need to minimize organ damage earlier and the role of early biologic initiation in modifying the natural SLE disease course. The symposium also aims to support clinicians in recognizing clinical characteristics where early biologic initiation should be considered in their practice and discusses applying the disease modification framework as a strategy to minimize organ damage. Developed and offered by GSK. Not an official program of the ACR.
Non-CME